Background: Sublingual buprenorphine/naloxone, a common treatment for opioid dependence, is frequently abused by intravenous injection. Inadvertent intra-arterial injection of buprenorphine/naloxone can produce acute ischemic insult to the hand due to gelatin embolism. Our purpose was to review a series of these patients in order to describe the clinical entity, review the outcomes, and propose a rational treatment algorithm. Methods: Clinical records of all patients evaluated by the hand surgery team between 2011 and 2015 for ischemia of the hand after buprenorphine/naloxone injection were reviewed. Treatment, complications, and amount of tissue loss were recorded. Patients presenting within 48 hours of the injection were treated with intravenous heparin for 5 days, followed by oral aspirin and clopidogrel for 30 days. Those presenting after 48 hours were treated with aspirin and clopidogrel only. Results: Ten patients presented during the review period. Average follow-up time was 13 weeks. Eight had ischemia of the radial side of the hand, 1 of the ulnar side, and 1 had bilateral ischemia. Three patients were treated with intravenous heparin and 5 with oral agents. Two presented with dry gangrene and did not receive anticoagulation. All patients experienced tissue loss. There was no difference in outcome regardless of treatment. Conclusions: With the increasing use of sublingual buprenorphine/naloxone in opioid dependency, ischemic hand injuries will be seen with greater frequency. Whereas outcomes did not vary with treatment modality in this series, further study is needed to determine the most effective treatment of these injuries.
Introduction
Opioid abuse remains a growing problem in the United States. The Substance Abuse and Mental Health Services Administration estimates that there are now approximately 2.5 million Americans suffering from opioid abuse and dependence, 10 and overdoses of opioid medications are responsible for more than 15,000 deaths annually. 11 This epidemic has renewed interest in the development of safer, more effective therapies for the treatment of opioid dependence. One of the most promising pharmacologic advancements in this field was the introduction of a combination medication, buprenorphine/naloxone (BNX), which is marketed under the trade name Suboxone (Monosol Rx LLC, Warren, New Jersey). Since receiving Food and Drug Administration approval in 2002, BNX has seen a rapid rise in popularity, with more than 10 million prescriptions issued annually. With multiple studies demonstrating its effectiveness and an improved safety profile when compared with its predecessors, such as methadone, BNX has now become first-line therapy for the treatment of opioid dependence. 13 Buprenorphine is a synthetic opioid which acts as a partial agonist of the mu opioid receptor. This activity enables the drug to reduce cravings for opioids while also preventing the symptoms of opioid withdrawal. Because it is only a partial agonist at the mu receptor, buprenorphine carries less risk of sedation, respiratory depression, and death than full agonist medications, such as methadone. In addition, it produces less physical dependence, making eventual cessation of the drug less difficult. 8 HAND 12 (5) To reduce abuse of buprenorphine, the full opioid antagonist, naloxone was added to the formulation. Due to low bioavailability when taken via the sublingual route, naloxone exhibits little effect when taken as intended. If administered parenterally, however, the drug's antagonistic effects can precipitate withdrawal in opioid abusers. 8 Although BNX was designed specifically to deter abuse, post-market surveillance of the drug has demonstrated limited success in this area. Commercially available BNX formulations contain naloxone in a 1:4 ratio with buprenorphine, limiting its ability to completely block the agonist effects of buprenorphine. Taking advantage of the relatively short halflife of naloxone compared with buprenorphine, intravenous abusers can use specific injection strategies to reduce the withdrawal effect of the naloxone component and obtain a "high" from the drug. 6 While many studies have shown reductions in the rates of injection of BNX when compared with buprenorphine alone, 2,4 others have shown that up to 20% of patients in opioid abuse treatment programs misuse BNX by intravenous injection. 5, 6 Initially developed as a sublingual tablet, BNX was reformulated into a mucoadherent sublingual film. The most common method for parenteral abuse is to dissolve the strips in a variable amount of water, filter the solution, and then inject the medication intravenously. 12 In recent years, the hand surgery team at the University of Kentucky Medical Center has noted an increasing number of patients presenting to the emergency room or outpatient clinics with ischemia of the hand and digits after inadvertent or intentional intra-arterial injection of sublingual BNX. When looking to the literature for guidance on the management of these patients, we found that very little had been written about these injuries. The purpose of our study was to review our experience with a series of these patients in order to describe the clinical entity, examine outcomes, and propose rational treatment options.
Methods
This study is a retrospective chart review. The inpatient and outpatient databases for all faculty hand surgeons in the Division of Plastic Surgery at the University of Kentucky were searched by International Classification of Diseases, Ninth Revision code to identify all patients evaluated for ischemia of the hand or digits after injection of sublingual BNX between 2011 and 2015.
The clinical records of all identified patients were reviewed. Patient age, comorbid medical conditions, smoking history, time of injection, and injection site were recorded, as well as information regarding medical and surgical treatments, complications, and amount of tissue loss.
Results
A total of 10 patients were identified during the reviewed period; 4 were male and 6 were female. Median patient age was 30 years, with a range from 20 to 46 years. All of the patients were regular smokers. The most common injection site was the volar wrist on the radial side (7 patients). One patient injected the thenar eminence, 1 in the proximal volar forearm, and 1 reported injection on the dorsum of the hand. Median time elapsed from injection to presentation was 4 days, with a range from 24 hours to 7 months.
Common symptoms in the affected digits at presentation included pain (all 10 patients), numbness and paresthesias (7 patients), and cold sensation (4 patients). Common physical exam findings in the affected portions of the hand included edema, decreased temperature, delayed capillary refill, cyanosis, and skin mottling.
Eight patients had ischemia of the radial side of the hand, 1 on the ulnar side, and 1 patient had bilateral symptoms. The extent of the ischemia ranged from distal to the distal interphalangeal joint only, to involvement of the entire length of the hand distal to the wrist crease.
With exception of 2 patients presenting more than 30 days after injection with dry gangrene, all patients were treated acutely by some form of anticoagulation. Three of the patients who presented within 72 hours of admission were admitted to the hospital and treated with daily aspirin 81 mg, intravenous heparin, elevation, and gentle warming of the affected hand for 3 to 5 days, followed by an outpatient regimen of 81 mg aspirin daily and either subcutaneous low molecular weight heparin (SQ LMWH) twice daily or clopidogrel 75 mg daily. Two other patients were treated with SQ LMWH as a bridge to warfarin therapy, 1 was treated with daily aspirin and clopidogrel, and 2 with daily aspirin only. Duration of therapy varied from 7 to 90 days.
Average follow-up time for this study was 13 weeks. All patients who returned for follow-up experienced some degree of digital tissue loss (Table 1) . Five patients required surgical intervention for debridement and reconstruction.
Case Example
M.S. is a 24-year-old unemployed female with no significant medical history who presented to the emergency department with pain, paresthesias, and cyanosis of the right index, long, and ring fingers 1 day after inadvertent injection of sublingual BNX into the radial artery. Physical exam demonstrated purplish discoloration of the index, long, and ring fingers with sluggish capillary refill (Figure 2 ). Radial and ulnar artery pulses were present at the wrist. Doppler exam demonstrated loss of digital artery signals distal to the proximal interphalangeal joint on the ulnar side of the index finger, radial side of the ring finger, and both sides of the long finger.
The patient was admitted to the hospital and anticoagulated with intravenous heparin, and 81 mg of aspirin was administered daily. The right hand was elevated and warmed. After 4 days of anticoagulation, improvement in pain was noted, and she was discharged to continue outpatient therapy with daily oral aspirin and clopidogrel.
Aspirin and clopidogrel therapy was continued for 3 months. Pain and discoloration of the fingers improved over this time, but the distal aspect of the index finger developed dry gangrene (Figure 3) , and amputation of the necrotic portion was performed at 4 months.
Discussion
Ischemic complications resulting from intra-arterial injection of recreational drugs is certainly not a new phenomenon and has been previously described with many drugs of abuse, including heroin, cocaine, and amphetamines. The proposed mechanisms by which drug injection causes ischemia are multiple. Intimal damage caused by direct cytotoxic effects, high osmolarity, or pH differences may result in endarteritis and thrombosis. Mechanical trauma and drugmediated vasoconstriction may play a role as well. Smaller Note. Treatment consisted of conservative amputation. The patient declined toe to thumb reconstruction.
Figure 2.
Twenty-four-year-old female presenting with pain and discoloration of the fingers on the right hand 1 day after injection of buprenorphine/naloxone into the radial artery.
Note. Treatment consisted of intravenous heparin for 4 days followed by oral aspirin and clopidogrel therapy. vessels distal from the site of injection may be occluded by injected particulates or substances which precipitate out of solution and crystallize after injection. 9 The true cause of injection-mediated ischemia is likely some combination of these mechanisms, dependent on both the drug used and the injection technique.
In the case of sublingual BNX, we suspect that gelatin embolism is the primary cause of ischemia in most patients. BNX films are comprised largely of hydroxypropyl methylcellulose, a synthetic gelatin substitute commonly used as a thickener in many food and cosmetic products. It is not surprising then, that abusers of BNX report that the films form a "jelly-like" substance after being mixed with water for injection. 12 Differences in water solubility at different temperatures and unreliable filtration methods, such as use of cotton or cigarette filters, likely result in injection of small gelatinous particles that cause distal vessel occlusion.
Despite incomplete understanding of the pathophysiology of ischemia after intra-arterial drug injection, most agree that vessel thrombosis plays an important role. As such, anticoagulation therapy aimed at preventing clot propagation and preserving collateral flow has traditionally formed the cornerstone of treatment. Other adjunctive therapies for ischemia after recreational drug abuse have included injection of local anesthetics, sympathetic nerve blocks, calcium channel blockers, prostacyclin analogues, and catheter-directed thrombolysis. 1, 9 Several cases of hand ischemia due to buprenorphine injection have been reported in the literature, including a case successfully managed with iloprost and dextran-40. In all of these cases, injection was with the crushed tablet form and not the sublingual film. 3, 7 Except for those who had already developed gangrene, all patients in our series were treated with some form of anticoagulation. With little evidence to guide treatment, the specific regimen and duration of therapy were variable, and treatment groups were too small to allow a meaningful comparison of outcomes. However, based on the overall experience of this series combined with the known literature on interarterial injection of recreational drugs, an initial treatment of anticoagulation is reasonable when the patient presents in the first 72 hours after injection. For later presentations, pain control and conservative amputations form the mainstays of treatment.
The growing popularity of sublingual BNX films for treatment of opioid dependence is likely to result in an increasing incidence of hand ischemia from inadvertent intra-arterial injection. As there is yet no reliable treatment for these patients, emphasis should be placed on prevention through education of both patients and prescribers of the potentially disastrous consequences of parenteral abuse. Further study will be needed to develop effective treatment.
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